United States Endometrial Cancer Market By Type of Cancer (Endometrial Carcinoma, Uterine Sarcomas), By Type of Therapy (Immunotherapy, Radiation Therapy, Chemotherapy, Other Types of Therapies), By Diagnosis Method (Biopsy, Pelvic Ultrasound, Hysteroscopy, CT scan, Other Diagnosis Methods), By Region, Competition Forecast & Opportunities, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 8.12 Billion
CAGR (2026-2031)	5.69%
Fastest Growing Segment	Biopsy
Largest Market	Midwest
Market Size (2031)	USD 11.32 Billion

Market Overview

The United States Endometrial Cancer Market will grow from USD 8.12 Billion in 2025 to USD 11.32 Billion by 2031 at a 5.69% CAGR. The United States Endometrial Cancer Market comprises therapeutic interventions such as chemotherapies, immunotherapies, and hormonal agents, alongside diagnostic tools designed to detect malignancies in the uterine lining. This market is primarily driven by the rising prevalence of obesity and diabetes, as well as an aging female demographic that is statistically more susceptible to the disease. These fundamental drivers create a sustained demand for effective management solutions and screening protocols. According to the American Cancer Society, in 2025, approximately 69,120 new cases of uterine cancer were estimated to be diagnosed in the United States, underscoring the substantial clinical burden supporting sector growth.

Despite these strong demand indicators, the market faces a significant challenge regarding the high cost of novel therapeutic regimens. The substantial financial investment required for advanced treatments often limits patient access and creates reimbursement hurdles that restrict broader adoption. This economic barrier is further compounded by the potential for adverse effects associated with aggressive therapies, which can impact patient compliance. Consequently, affordability issues remain a critical impediment that could slow the overall expansion of the market despite the increasing incidence rates.

Key Market Drivers

The integration of advanced immunotherapies and targeted therapeutics constitutes the most transformative driver for the United States Endometrial Cancer Market, fundamentally reshaping clinical standards for advanced disease management. This shift is characterized by the regulatory movement from traditional chemotherapy-only protocols to precision-based immune checkpoint inhibitor regimens, which have demonstrated superior efficacy in reducing mortality. According to GSK, August 2024, in the 'RUBY phase III trial' update, the combination of dostarlimab (Jemperli) and chemotherapy demonstrated a 31% reduction in the risk of death compared to chemotherapy alone in the overall patient population, a milestone that supported a broad FDA approval for all adult patients. Such high-impact clinical data not only expands the addressable patient pool beyond the mismatch repair deficient (dMMR) subgroup but also justifies the premium pricing of these biologics, thereby driving substantial revenue growth within the sector.

Concurrently, the market trajectory is heavily influenced by the alarming rise in mortality rates and the widening disparity in clinical outcomes among specific demographic groups. Unlike many other malignancies where survival trends are improving, endometrial cancer is witnessing a lethality increase that necessitates the urgent adoption of more aggressive and effective therapeutic interventions. According to the American Cancer Society, January 2025, in the 'Cancer Facts & Figures 2025' report, the mortality rate for uterine cancer in the United States has been rising by approximately 1.5% per year, marking it as one of the few cancers with a worsening death trajectory. This escalating burden creates a critical commercial imperative for the development of novel treatments, a demand reflected in the financial performance of leading oncology assets. According to Merck & Co., February 2025, in the 'Fourth Quarter and Full Year 2024 Results', global sales for Keytruda reached $29.5 billion in 2024, driven significantly by increased uptake in earlier-stage cancers and women's oncology indications.

Download Free Sample Report

Key Market Challenges

The primary challenge impeding the growth of the United States Endometrial Cancer Market is the prohibitive cost associated with novel therapeutic regimens, particularly advanced immunotherapies and combination agents. While these treatments offer improved clinical efficacy, their elevated pricing structures create significant barriers to widespread market adoption. Insurance providers and healthcare payers often implement stringent reimbursement criteria to mitigate these expenses, leading to coverage denials or substantial out-of-pocket requirements for patients. This economic friction restricts the volume of the addressable patient population that can access these therapies, effectively lowering sales velocity and limiting the revenue potential of otherwise high-demand drugs.

Furthermore, this financial burden creates a bottleneck where clinical need does not automatically translate into market expansion. High treatment costs frequently result in "financial toxicity," causing patients to delay or discontinue care, which negatively impacts medication adherence rates and overall treatment volumes. According to the American Cancer Society, in 2025, the median annual cost for a course of an oncology drug reached approximately $196,000. This substantial capital intensity forces healthcare systems to ration resources, thereby slowing the overall commercial scaling of the United States Endometrial Cancer Market despite the rising incidence of the disease.

Key Market Trends

The integration of molecular classification into routine clinical diagnostics represents a fundamental shift from traditional histology-based stratification to genomic profiling, enabling highly personalized treatment strategies in the United States Endometrial Cancer Market. Clinicians are increasingly utilizing The Cancer Genome Atlas (TCGA) classification system to categorize tumors into distinct molecular subtypes, such as POLE-ultramutated and p53-abnormal, which allows for the precise tailoring of adjuvant therapies and the potential de-escalation of toxic treatments for low-risk groups. This transition is rapidly gaining traction in clinical practice as providers seek to address the disease's heterogeneity more effectively than standard pathology permits. According to the American Society of Clinical Oncology, March 2025, in the 'Real-World Molecular Testing Rates and Patterns' report, the adoption of biomarker testing for patients with advanced or recurrent endometrial cancer has surged, reaching a utilization rate of 89% in clinical settings, significantly driven by updated guideline recommendations.

Simultaneously, the expansion of robotic-assisted minimally invasive surgeries is establishing a new standard of care for the surgical management of endometrial malignancies, replacing open laparotomy and conventional laparoscopy. This technological adoption is driven by the ability of robotic platforms to offer superior precision during hysterectomies and lymph node assessments, significantly reducing perioperative morbidity and hospital lengths of stay while maintaining oncological safety. The long-term clinical benefits of this surgical modality are becoming increasingly evident, supporting its widespread implementation across major United States healthcare systems to optimize patient recovery. According to Contemporary OB/GYN, March 2025, in the 'Robotic-assisted laparoscopy increases endometrial cancer survival rates' article, a randomized controlled trial demonstrated that patients undergoing robotic-assisted surgery achieved a 10-year overall survival rate of 85.4%, surpassing the 75.5% rate observed in the conventional laparoscopy group.

Segmental Insights

The Biopsy segment is currently positioned as the fastest growing area within the United States Endometrial Cancer Market, largely due to the critical emphasis on early detection and minimally invasive diagnostics. This expansion is supported by the increasing adoption of office-based sampling procedures that offer efficient alternatives to traditional surgical methods. Additionally, the American College of Obstetricians and Gynecologists advocates for immediate tissue evaluation in patients presenting with abnormal uterine bleeding. These clinical guidelines, combined with rising disease prevalence, drive the sustained demand for biopsy devices throughout the American healthcare sector.

Regional Insights

The Midwest currently holds the leading position in the United States Endometrial Cancer Market. This regional dominance is primarily driven by a high prevalence of specific risk factors, particularly obesity, which correlates with increased incidence rates across these states. Furthermore, the region benefits from a dense concentration of centralized healthcare infrastructure and major academic medical centers, such as the Mayo Clinic, which facilitate early diagnosis and the adoption of advanced therapeutic interventions. Comprehensive market analysis suggests that this combination of elevated patient demand and accessible specialized care sustains the Midwest's status as the primary revenue generator within the national landscape.

Recent Developments

• In November 2025, Promega Corporation announced the FDA approval of its OncoMate MSI Dx Analysis System as a companion diagnostic for the United States Endometrial Cancer Market. This molecular diagnostic tool was cleared to help identify patients with microsatellite-stable (MSS) endometrial carcinoma who are eligible for treatment with a specific combination of pembrolizumab and lenvatinib. By analyzing the microsatellite instability status in tumor tissue, this polymerase chain reaction-based test aids clinicians in making precise treatment decisions. This product launch underscores the growing importance of diagnostic collaborations in ensuring patients receive the most appropriate targeted therapies for advanced gynecologic malignancies.
• In August 2024, GSK reported that the FDA granted expanded approval for Jemperli in combination with carboplatin and paclitaxel for the treatment of adult patients with primary advanced or recurrent endometrial cancer. This decision broadened the drug's indication to include all patients regardless of their mismatch repair status, whereas previous approvals were restricted to those with mismatch repair deficient tumors. The regulatory endorsement was driven by results from Part 1 of the Phase III RUBY trial, which demonstrated a statistically significant and clinically meaningful improvement in overall survival for the combined therapy versus chemotherapy alone in the overall patient population.
• In June 2024, AstraZeneca announced that the United States Food and Drug Administration (FDA) approved its immunotherapy agent, Imfinzi, in combination with carboplatin and paclitaxel followed by monotherapy for specific endometrial cancer patients. This regulatory authorization specifically covers adult patients with primary advanced or recurrent endometrial cancer that is identified as mismatch repair deficient (dMMR). The approval was supported by data from the Phase III DUO-E trial, which demonstrated a statistically significant reduction in the risk of disease progression or death for this regimen compared to chemotherapy alone. This development offers a new therapeutic option for patients with this specific genetic biomarker.
• In June 2024, Merck received FDA approval for its anti-PD-1 therapy, Keytruda, combined with carboplatin and paclitaxel, followed by single-agent use, for the treatment of primary advanced or recurrent endometrial carcinoma. This regulatory decision marked a significant advancement as it authorized the regimen for adult patients regardless of their mismatch repair status, distinguishing it from previous limited indications. The approval was based on findings from the Phase 3 NRG-GY018 clinical trial, where the combination therapy showed a substantial improvement in progression-free survival compared to the standard chemotherapy and placebo regimen. This launch solidifies the company's position in the frontline treatment landscape.

Key Market Players

• Merck & Co. Inc
• Pfizer Inc
• AstraZeneca PLC
• Eli Lilly and Company
• Roche Holding AG
• Novartis International AG
• Bristol‑Myers Squibb Company
• GlaxoSmithKline PLC
• Seattle Genetics Inc
• Genentech Inc

By Type of Cancer	By Type of Therapy	By Diagnosis Method	By Region
Endometrial Carcinoma Uterine Sarcomas	Immunotherapy Radiation Therapy Chemotherapy Other Types of Therapies	Biopsy Pelvic Ultrasound Hysteroscopy CT scan Other Diagnosis Methods	Northeast Midwest South West

Report Scope:

In this report, the United States Endometrial Cancer Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• United States Endometrial Cancer Market, By Type of Cancer:

• Endometrial Carcinoma
• Uterine Sarcomas

• United States Endometrial Cancer Market, By Type of Therapy:

• Immunotherapy
• Radiation Therapy
• Chemotherapy
• Other Types of Therapies

• United States Endometrial Cancer Market, By Diagnosis Method:

• Biopsy
• Pelvic Ultrasound
• Hysteroscopy
• CT scan
• Other Diagnosis Methods

• United States Endometrial Cancer Market, By Region:

• Northeast
• Midwest
• South
• West